Core Insights - OneMedNet Corporation has expanded its capabilities within the Datavant Connect platform to enhance healthcare data discovery, analytics, and partner assessment processes, emphasizing the importance of secure and scalable data solutions in healthcare innovation [1][4] - The healthcare industry is generating vast amounts of health-related data, which is often fragmented and siloed, creating challenges in accessibility and usability [2][5] - OneMedNet will utilize AWS Clean Rooms to provide secure collaboration environments for data partner assessment, enhancing data security and privacy without direct data movement [3][4] Company Overview - OneMedNet is a leader in providing regulatory-grade imaging Real-World Data (iRWD), leveraging over 1,400 healthcare sites to unlock the potential of healthcare data [5] - The company’s iRWD™ platform supports various sectors, including rare diseases, oncology, and cardiology, delivering insights that drive innovation in patient care and healthcare disruption [5][6] - Beyond healthcare, OneMedNet's AI technology anonymizes data for other industries such as finance and retail, enabling secure data sharing and project de-risking [6]

Core Insights - ECD Auto Design has introduced a new 700+ horsepower BLUEPRINT V8 engine, available as an upgrade for the Defender lineup and Range Rover Classic builds, marking a significant enhancement in performance options for luxury SUVs [2][9]. Company Overview - ECD Auto Design is a public company listed on NASDAQ under the ticker ECDA, specializing in the restoration of luxury vehicles, combining classic aesthetics with modern performance [10]. - Founded in 2013 by three British automotive enthusiasts, the company operates from a 100,000-square-foot facility in Kissimmee, Florida, employing 105 skilled craftsmen with extensive certifications [10]. Product Development - The new BLUEPRINT V8 engine is a response to client demand, integrating decades of experience with LS-based drivetrains to deliver a powerful yet classic driving experience [3][4]. - Key upgrades for the 700+ HP configuration include a new front-end rotating assembly, enhanced cooling systems, upgraded transmission and differentials, and refined ECU tuning [7][5]. Market Positioning - The 700HP option is designed for clients seeking a blend of classic design and modern performance, appealing to performance-focused collectors and luxury clients [9][8]. - ECD emphasizes a bespoke process, allowing clients to customize their vehicles extensively, with each build taking approximately 2,200 hours to complete [10].

Group 1 - Golar's Q1 2025 results will be released before NASDAQ opens on May 27, 2025, due to a scheduled official State visit to the GTA Hub in Mauritania and Senegal [1] - A webcast presentation will take place at 1:00 P.M (London Time) on the same day, and it will be available for download from the Investor Relations section of the company's website [1] - Participants are encouraged to join the conference call via the live webcast link, with a recommendation to connect 10 minutes prior to the call start [1] Group 2 - For the teleconference, participants must register to obtain dial-in and passcode details, which helps eliminate wait times [3] - Participants can join the call by dialing in with provided numbers and their unique PIN or by using the "Call me" option for instant connection [3] - Presentation materials can be downloaded from the company's website to view while listening to the conference [4] Group 3 - A replay of the event audio will be available for a limited time on the company's website for those unable to listen live [4] - The information is subject to disclosure requirements under the Norwegian Securities Trading Act [4]

Indication Has Been Granted FDA Breakthrough Device Designation for Potential PMA FilingDENVER, May 13, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today that it has successfully reached the halfway point in the NEUTRALIZE-AKI pivotal clinical trial, enabling a per protocol prespecified interim analysis by the trial’s ...

Announced accepted oral presentation of positive phase 3 randomized placebo controlled clinical trial results of CAN-2409 (aglatimagene besadenovec) in localized prostate cancer at the 2025 American Society of Clinical Oncology (ASCO) Annual MeetingPreparations on track for Biologics License Application (BLA) for CAN-2409 in intermediate-to-high-risk localized prostate cancer, with submission expected in Q4 2026Recently announced both prolonged median overall survival (mOS) and a long tail of survival in an ...

Interim Management Statement covering Q3 2024/25 The Board of Directors of Rovsing A/S has today reviewed and approved the Interim Management Statement for the third quarter (1 January 2025– 31 March 2025) of the financial year 2024/25. Q3 highlights In Q3 2024/25, the revenue amounted to DKK 7.5 million (Q3 2023/24: DKK 9.5 million). EBITDA in Q3 amounted to DKK -0.4 million (Q3 2023/24: DKK 0.8 million).Order intake in Q3 amounted to DKK 9.3 million. During Q3 and to date, the Company signed new contracts ...

SAN DIEGO, May 13, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or “VivoSim”) announced today that its NAMkind™ platform for intestinal efficacy prediction was recognized with a blue ribbon “Poster of Distinction” award at the Digestive Disease Week Conference (San Diego, CA, May 2-6, 2025). The work describes developing a robust, multicellular in vitro model that closely mirrors human intestinal biology, paving the way for safer and more effective therapies for inflammatory bow ...

AUSTIN, Texas, May 13, 2025 (GLOBE NEWSWIRE) -- FTC Solar, Inc. (Nasdaq: FTCI), a leading provider of solar tracker systems, software and engineering services, today announced that members of its management team, including CEO Yann Brandt, are scheduled to participate in meetings with investors at the following upcoming conferences: CLEANPOWER 2025 – May 20, 2025, Phoenix. The company will participate in group investor meetings with analysts from UBS, Guggenheim, and Roth Securities. Bank of America Power, ...

Core Insights - Glucotrack, Inc. has received ethical approval for a long-term clinical study of its continuous blood glucose monitor (CBGM) for type 1 and type 2 diabetes patients [1][2] - The study will enroll up to 30 participants and evaluate the device's performance and safety over an initial period of 1 year, with potential extension to 3 years [2][4] - The CBGM is designed to provide real-time blood glucose measurements directly from blood, offering advantages over traditional systems that measure interstitial fluid [3][4] Company Overview - Glucotrack, Inc. focuses on the design, development, and commercialization of innovative technologies for diabetes management [6] - The CBGM is a long-term implantable system with a sensor longevity of up to 3 years and minimal calibration required [7] Clinical Study Details - The study will be led by Professor David O'Neal and will take place at St. Vincent's Hospital Melbourne [2][3] - The first patient implants are expected to occur by July 2025 [2] - The study aims to address key challenges faced by diabetes patients, including the need for extended sensor life and the elimination of on-body wearables [4]

Construction in Melbourne, FL expected to commence in Third Quarter 2025 Lantana, Fla., May 13, 2025 (GLOBE NEWSWIRE) -- JFB Construction Holdings (Nasdaq: JFB), a construction company focused on commercial, retail, and residential property development (“JFB” or the “Company”), today announced that it has signed a contract to develop a project for Marriot Hotels in Melbourne, Florida. The project is a conversion and remodel of an existing Holiday Inn to a Courtyard by Marriott in Melbourne, Florida. The con ...